OncoMatch/Clinical Trials/NCT06744920
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Is NCT06744920 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Remibrutinib (Blinded) and Remibrutinib (Open Label) for generalized myasthenia gravis.
Treatment: Remibrutinib (Blinded) · Remibrutinib (Open Label) — A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening
Demographics
Prior therapy
Must have received: standard-of-care treatment
Participants who have been on a stable dose of standard-of-care treatment as specified in the protocol
Cannot have received: intravenous immunoglobulin
treated with intravenous immunoglobulins ... in the past month
Cannot have received: plasma exchange
treated with ... plasma exchange (IVIg/PLEX) in the past month
Cannot have received: anti-CD20 antibody (rituximab)
treated with ... rituximab in the past 6 months
Cannot have received: C5 complement inhibitor (eculizumab)
treated with ... eculizumab in the past 2 months
Cannot have received: C5 complement inhibitor (ravulizumab)
treated with ... ravulizumab or other complement inhibitors in the past 3 months
Cannot have received: complement inhibitor
treated with ... other complement inhibitors in the past 3 months
Cannot have received: anti-FcRn therapy (efgartigimod)
treated with ... efgartigimod or other anti-FcRn therapies in the past 3 months
Cannot have received: anti-FcRn therapy
treated with ... other anti-FcRn therapies in the past 3 months
Cannot have received: surgery
had a thymectomy in the past 6 months or a planned thymectomy during the trial period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Neuromuscular Research Center · Phoenix, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- Fullerton Neuro and Headache Ctr · Fullerton, California
- University Of Southern California · Los Angeles, California
- Univ Cali Irvine ALS Neuromuscular · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06744920 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior intravenous immunoglobulin, plasma exchange, anti-CD20 antibody disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS II or MGFA CLASS III or MGFA CLASS IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify